Market News
Thursday, September 1, 2016
BRIEF-Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3
* Cytokinetics and Amgen to advance Omecamtiv Mecarbil to
phase 3 clinical development
Read more
No comments:
Post a Comment
‹
›
Home
View web version
No comments:
Post a Comment